Svar 公司专注于大分子配体结合分析和基于细胞的分析研究，在抗体和多肽药物、基因和载体的治疗方面丰富有经验，涉及领域包括肿瘤学、自身免疫、内分泌疾病和神经学相关研究领域，同时提供相关领域疾病的药物和解决方案，提供完整的CRO 产品。
北京博蕾德生物是Svar 公司授权的中国区总代理，更多Svar 公司产品信息，请咨询北京博蕾德生物科技有限公司。
以下是Svar 公司授权博蕾德生物为中国区总代理授权书。
特色产品推荐：
**补体检测试剂盒1）药物开发-补体靶向治疗研究表明,炎性疾病的发生、发展同补体的活化有关。因此,如何干扰和抑制补体活化产生的有害作用,成为药理学研究的焦点之一，Euro Diagnostica试剂盒用于评估补体靶向治疗效果（参考文献4-8）。
2）
临床研究-补体功能/活性监测补体功能的评估在补体相关疾病的发生和治疗中具有重要意义。文献5-9 用Euro Diagnostica试剂盒监测补体疾病治疗中补体水平。
3）补体脱靶反应在某些情况下，补体激活可引起严重反应，比如候选药物的脱靶反应，抗体依赖的补体激活，移植排斥反应。（（参考文献12-13）。）
订购信息
| 货号 |
产品名称 |
规格 |
| COMPL300 |
Complement system Screen WIESLAB® |
96T |
| COMPLCP310 |
Complement system Classical Pathway WIESLAB® |
96T |
| COMPLMP320 |
Complement system MBL pathway WIESLAB® |
96T |
| COMPLAP330 |
Complement system Alternative Pathway WIESLAB® |
96T |
应用文献：1.Ricklin D and Lambris JD.Complement in Immune and Inflammatory Disorders:Therapeutic Interventions. J Immunol 2013; 190: 3839-3847
2. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of
the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005; 296: 187–198
3. Salvesen B and Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Mol Imm 2009;6:1620-1625
4.Hill A et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results. Abstract 2413 ;58th ASH Annual Meeting 2015
5. Jore MM et al. Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology 2016: doi:10.1038/nsmb.3196
6. Würzner R et al. Assessment of complement activity by ELISA. Abstract #41 16th Biennial Meeting of the European Society for Immunodeficiencies, ESID 2014
7. Kocsis A. Selective Inhibition of the Lectin Pathway of Complement with
Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine
Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway
Activation. J of Immunol 2010;185: 4169–4178
8. Kadam A P and Sahu A Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. J of Immunol 2010;184: 7116-24
9. Volokhina E B et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160: 237–43
10. Heinen S et al. Monitoring and modeling treatment of atypical hemolytic uremic
syndrome. Molecular Immunology 2013; 54:84– 88
11. Hallenstensen RF et al. Eculizumab treatment during pregnancy does not affect the
complement system activity of the newborn. Immunobiology 2015; 220:452–459
12. Castellano G et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion- Induced Renal Damage. Am J Pathol 2010; 176:1648–1659
13. Brennan FR et al. Safety and immunotoxicity assessment of immunomodulatory
monoclonal antibodies. mAbs 2010; 2:3, 233-255
14. Mitsuru Sugimoto,etal.Possible participation of IgG4 in the activation of complement in IgG4-related disease with hypocomplementemia.Modern Rheumatology,Volume 26, 2016 - Issue 2
15．Y. Palarasah,etal.Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system.Clincal&Experimental Immunology,Volume164, Issue3,June 2011,Pages 388-395.
